Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of 3 intra-nodal injections of GAD-alum (Diamyd),
together with oral vitamin D supplementation. Safety and feasibility of the treatment will be
evaluated and also effects on the immune system and on the preservation of endogenous insulin
production.
Phase:
Phase 2
Details
Lead Sponsor:
Norwegian University of Science and Technology
Collaborators:
Diamyd Medical AB Karolinska Institutet Karolinska University Hospital Linkoeping University St. Olavs Hospital